John Ballew joined the T1D Fund in 2021. Prior to working at the Fund, he held roles in the Global Oncology Business Unit and the Center for External Innovation (CEI) working in R&D business development at Takeda Pharmaceuticals. John also worked at Putnam Associates, where he served numerous global biopharmaceutical clients on strategic projects ranging from pre-clinical assessments through loss of exclusivity.
John holds a PhD in Biomolecular Science & Engineering from the University of California at Santa Barbara where he developed a novel antibody-based diagnostic methodology which supported the founding of Serimmune, an immune mapping platform technology company. During his graduate studies, he also earned a degree in Technology Management and assisted business development efforts while working at Aptitude Medical Systems. Subsequently, he extended his research into single cell analysis, with a focus on Type 1 Diabetes, as a Postdoctoral Associate at the Koch Institute for Integrative Cancer Research at MIT. Additionally, John was a Flagship VentureLabs Fellow, Whitaker International Fellow in Biomedical Engineering, and former President of the Consulting Club at MIT.